ROCK — Gibraltar Industries, Inc. · 2026-09-05 · Verdict: WATCH · Conviction 3
Price $47.25 (screen row in universe_under2b.csv, screen run dated 2026-09-05; no live prices in this sandbox) · Mkt cap $1,402.6M · EV $2,605.5M · EV/EBIT 21.2x on the screen's stale CY2025 GAAP EBIT, 8.2x EV to guided 2026 adjusted EBITDA · FCF yield 8.6% on the screen, 6.5% on 2025 continuing-operations FCF · Net debt $(1,202.9)M · ADV $10.7M
Sources read: 10-K 2026-02-26 (Items 1, 1A, 7), 10-Q 2026-08-05, DEF 14A 2026-04-06, 8-Ks 2026-04-17 (OmniMax audited financials and pro formas), 2026-05-07 and 2026-08-05 (results), Form 4s (12m). No transcript in the bundle; remarks taken from the earnings-release 8-Ks.
1. What the business actually does
Gibraltar makes building products in three segments. Residential (83% of Q2 2026 revenue) sells roof trim, flashings, soffit, gutters, ventilation, metal roofing and cluster mailboxes through home centers, wholesalers and roofing distributors; one home improvement retailer was 12% of 2025 sales. Agtech builds commercial greenhouses and structural canopies; Infrastructure makes bridge bearings, expansion joints and pavement seals (10-K 2025, Item 1). Two events reshaped 2026: Renewables was sold in two pieces and is now discontinued operations, and OmniMax was bought on 2026-02-02 for $1.335 billion cash, funded with a $650M term loan A, a $650M term loan B and revolver borrowings (10-Q Q2 2026).
2. Why it is mispriced: the edge case
The screen artifact is real and specific. The screen charges CY2025 GAAP EBIT of $122.8M and a CY2025 net loss of $44.4M against a post-deal enterprise value of $2.61B, giving 21.2x. The loss is entirely discontinued Renewables; continuing operations earned $97.6M, or $3.25 diluted (Q2 2026 release). Against the twice-reiterated 2026 outlook of $310-326M adjusted EBITDA and $3.65-4.05 adjusted EPS (8-K 2026-08-05), the same EV is 8.0-8.4x and the same price 11.7-12.9x.
What I cannot find is a seller. No spin, no index deletion, no liquidation appears in the bundle. The register is index and quant money: BlackRock 15.6%, FMR 12.5%, Vanguard 10.1%, Dimensional 6.0% (DEF 14A, as of 2026-03-16), on $10.7M of daily volume. The stock is 36.6% off its 52-week high but has already risen 26% from the $37.44 where the CEO bought in May. An artifact without a seller caps this at WATCH, rightly, because the artifact is not what holds the price down. Leverage is.
3. Unit economics and growth
Q2 2026 net sales were $509.5M, up 64.6%, of which $184.5M came from acquisitions and 5% was organic price. Building products organic revenue grew 12.7%, or 15.5% assuming OmniMax owned a year earlier, into what management calls a "flat-to-down market" (8-K 2026-08-05). Adjusted EBITDA was $88.0M, up 59.7%; Residential adjusted EBITDA margin was 19.0%, up 340bps sequentially but down 220bps year over year, and gross margin fell to 25.9% from 28.4% on price/cost, production inefficiency and integration. Agtech backlog is $66.2M, down 34% year over year and down from $84M at Q1 (10-Q Q2 2026).
The acquired asset is the crux, and its audited accounts are in the bundle. OmniMax standalone 2025: net sales $517.6M, operating income $38.5M (7.4% margin), D&A $42.7M, other operating charges $16.2M, interest expense $56.4M, pretax loss $16.8M, its second consecutive pretax loss (8-K/A 2026-04-17, Ex-99.1). EBITDA was $81.2M, about $97.4M adding back other operating charges, so Gibraltar paid roughly 13.7x adjusted EBITDA and 2.58x sales, or 10.5x with the full $29.4M of synergies, while its own equity trades at 8.2x. The growth was bought too: OmniMax's $35.4M of 2025 revenue growth came alongside its own acquisitions of Hancock ($107.7M) and Nu-Ray, so organic revenue very likely fell (Ex-99.1, Note 7). The pro forma settles it: on a full-year 2025 combined basis, operating income was $129.0M against Gibraltar's own $122.8M, interest expense $80.3M, and diluted EPS $1.23 against the $3.25 actually earned (Ex-99.2). Reported 2025 ROIC of 18.3% was struck on average invested capital of $599M (DEF 14A, Appendix A); on the roughly $2.08B now carried the same profit implies high single digits, so the deal halved the metric the proxy calls its most important measure.
4. Balance sheet and capital allocation
Long-term debt was $1,218.1M against $15.1M of cash at 2026-06-30, so net debt is $1,202.9M, 3.8x the guided EBITDA midpoint. Term loan A and the revolver mature 2031, term loan B 2033, with $470.3M of revolver availability. Covenants require maximum total net leverage of 5.25x stepping to 4.25x and minimum interest coverage of 3.00x (10-Q Q2 2026). Q2 interest expense of $21.0M annualizes near $84M, so guided EBITDA covers interest about 3.8x, closer to the covenant floor than the leverage ratio suggests. The $200M buyback authorized in April 2025 is entirely unused, after $60.0M went on 914,679 shares at about $65.6 in H1 2025; share count rose 0.6% year over year. Insiders own 0.9% as a group, but the Form 4s run one way: 22,135 shares bought for $823,334 by three insiders with zero sales, led by CEO Bill Bosway's 19,735 shares at $37.4377 on 2026-05-26.
5. Management: said versus did
Guidance was reiterated at Q1 and again at Q2, and synergies raised twice, from $26.0M to $29.4M with $17.0M in 2026 (8-Ks 2026-05-07, 2026-08-05). Q2 delivered the specific Q1 promise that March and April price actions across 14 residential brands "will create positive price material economics for us in the second quarter." The longer record is poor: $100 invested at the end of 2020 was worth $69 at the end of 2025 against $200 for the S&P SmallCap 600 Industrials (DEF 14A, Pay Versus Performance).
6. Valuation
The year rests on one number. H1 2026 adjusted EBITDA was $137.0M ($49.0M plus $88.0M), so the guide needs $173-189M in H2, up 26-38%, in a business whose 10-K calls Q1 and Q4 seasonally weakest and whose H2 2025 came in 10% below H1 2025. Repeating Q2 twice gets $176M, the low end. The bridge is OmniMax annualizing (Q1 held two months), synergies weighted to H2, and the 630-location award starting in Q4.
Base (50%): 2027 adjusted EBITDA $330M with synergies fully in and residential flat, 8.5x, net debt down to about $1.02B, roughly $60 per share. Bear (25%): residential falls another year and price/cost reverses, $260M at 7.5x with little deleveraging, about $27. Bull (25%): the guide's high end plus the national award annualizing into a housing recovery, $365M at 9.5x, about $84. Probability-weighted value is $57.75, 22% above $47.25, against a bear case 43% below.
Reverse DCF: at $47.25 plus $1,202.9M of net debt, the market pays $2.61B for guided 2026 NOPAT of roughly $166M (adjusted EBITDA $318M less about $78M of run-rate D&A at the 28% Q2 tax rate), a 6.4% unlevered after-tax yield, which at a 9% cost of capital implies about 2.5% perpetual growth: deliver the guide, then grow with inflation.
7. Catalysts and timeline
Q3 results in early November settle the H2 question. The 630-location award ships from Q4, and February 2027 guidance shows whether the full $29.4M of synergies is in the base. With Renewables divested, 2027 GAAP earnings should equal continuing earnings, which is when screens re-rate the name.
8. Risks and pre-registered kill criteria
Risks: 3.8x leverage into a market management calls flat-to-down; steel and aluminum tariffs; a 12% customer; an integration in month seven still counting synergies; Agtech backlog down 34%; and discontinued-operations liabilities of $72.3M against $71.1M of assets, after discontinued operations consumed $47.4M of cash in H1.
- Full-year 2026 adjusted EBITDA below $300M, by guidance cut or miss.
- Adjusted EBITDA to interest expense below 3.5x for two consecutive quarters (Q2 2026 was about 4.2x annualized; the covenant floor is 3.00x).
- Residential adjusted EBITDA margin below 17.0% for two consecutive quarters (Q2 2026: 19.0%).
- Net insider selling above $1M, or four more quarters with zero shares repurchased under the $200M authorization while the stock trades below $50.
9. Verdict and summary
WATCH, conviction 3. The screen's 21.2x is a genuine artifact, since the CY2025 loss is discontinued Renewables and continuing operations earned $3.25, so the same $2.61B EV is 8.2x the twice-reiterated 2026 adjusted EBITDA guide. But no forced seller exists, the stock has already recovered 26% from where three insiders bought in May, and the audited OmniMax accounts show what was done: $1.335 billion, about 13.7x adjusted EBITDA and 2.58x sales, for a business that lost money pretax in both 2024 and 2025 and whose 7% revenue growth was bought with its own acquisitions, funded entirely with debt, while Gibraltar's own equity trades at 8.2x and pro forma 2025 EPS was $1.23 against the $3.25 actually earned. What holds the price down is leverage of 3.8x into a market management calls flat-to-down, not a database error, and the decisive fact is arithmetic: H1 delivered $137.0M of adjusted EBITDA against a guide needing $173-189M in H2, when Q4 is seasonally weakest. Probability-weighted value of $57.75 is 22% above price with a bear case 43% below. Wait for the Q3 print.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.